Assessing equity in the distribution of bilateral development assistance for health, 1990-2010
This study utilizes publicly-available data on annual bilateral DAH from 23 donor countries to 135 recipient countries, between 1990 and 2010; and recipient country disease burden, measured by annual all-cause disability-adjusted life-years (DALYs), for five-year intervals from 1990 to 2010. Multiple log-linear regression models are used to assess the variation in DAH per DALY, by donor country and year.
Key findings indicate that variation between recipient countries in bilateral DAH per DALY has increased over time (DAH per DALY: SD=$1.76 in 1990, $2.61 in 2010.) Donor countries vary substantially in their distributional equity of bilateral DAH per DALY to different recipient countries (coefficient of variation among donors in 2010: min=1.40, max=5.40.)
This study highlights important global inequities in the allocation of bilateral DAH. Using disease burden as an objective measure of health need in each country, there is wide variation in the amount of bilateral DAH provided to countries to improve population health, given need. Explicit use of disease burden measurements is recommended to allocate health aid more equitably, and further investigation of country-specific factors dictating disbursement decisions is warranted.
Learning Areas:Public health or related public policy
Demonstrate the utility of disease burden as an objective and comparable measure of health need in each country Analyze the distributional equity of bilateral development assistance for health, by donor country and over time
Keyword(s): Funding/Financing, International Health
Qualified on the content I am responsible for because: I completed a three year research fellowship at the Institute for Health Metrics and Evaluation, the organization that produced the two key datasets used in this analysis. I have several years of graduate-level training and work experience utilizing statistics to assess trends in health indicators within and across countries.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.